LumiraDx Receives UK CTDA Approval For COVID Ultra And COVID & RSV Tests
Portfolio Pulse from Bill Haddad
LumiraDx has received approval from the UK's CTDA for its COVID Ultra and COVID & RSV tests, which will allow the company to market and sell these products in the UK.
June 20, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LumiraDx received UK CTDA approval for its COVID Ultra and COVID & RSV tests, allowing the company to market and sell these products in the UK.
The approval from the UK's CTDA for LumiraDx's COVID Ultra and COVID & RSV tests is a significant milestone for the company. This will allow LumiraDx to market and sell these products in the UK, potentially increasing its revenue and market share. As a result, this news is likely to have a positive short-term impact on LMDX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100